Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen

Jacobus, S.J.; Rajkumar, S.V.; Weiss, M.; Stewart, A.K.; Stadtmauer, E.A.; Callander, N.S.; Dreosti, Lydia M.; Lacy, M.Q.; Fonseca, R.

Please note that UPSpace will be unavailable from Friday, 2 May at 18:00 (South African Time) until Sunday, 4 May at 20:00 due to scheduled system upgrades. We apologise for any inconvenience this may cause and appreciate your understanding.

Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen

Jacobus, S.J.; Rajkumar, S.V.; Weiss, M.; Stewart, A.K.; Stadtmauer, E.A.; Callander, N.S.; Dreosti, Lydia M.; Lacy, M.Q.; Fonseca, R.

URI: http://hdl.handle.net/2263/56760

Date: 2016

Abstract:

Long-awaited results from the the Southwest Oncology Group (SWOG) trial comparing bortezomib–lenalidomide-dexamethasone (VRd) versus lenalidomide-dexamethasone (Rd) as induction treatment for previously untreated multiple myeloma (MM) patients were recently presented (S0777).1 Results justified the early adoption of VRd in the frontline setting over 5 years ago by the NCCN based on Level 2A evidence according to their guidelines.2 The randomized study E1A05 also sought to evaluate VRd superiority over a doublet (Vd), but in the consolidation setting. The trial was closed to enrollment prematurely due to slow accrual. Results reported here include 48 enrolled patients.

Show full item record